GLP-1 receptor agonists are effective treatments for obesity but are less accessible worldwide than pharmacological treatments for diabetes, reflecting biases and lack of education, and perpetuating health inequalities.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Michaelidou, M., Pappachan, J. M. & Jeeyavudeen, M. S. World J. Diabetes 14, 396–411 (2023).
Gomez, G. & Stanford, F. C. Int. J. Obes. 42, 495–500 (2018).
Bessesen, D. H. & Van Gaal, L. F. Lancet Diabetes Endocrinol. 6, 237–248 (2018).
Washington, T. B. et al. Gastroenterol Clin North Am 52, 429–441 (2023).
Nauck, M. A. & Meier, J. J. Diabetes Obes. Metab. 20, 5–21 (2018).
Drucker, D. J. Mol. Metab. 57, 101351 (2022).
Chatterjee, S., Khunti, K. & Davies, M. J. Lancet 389, 2239–2251 (2017).
ElSayed, N. A. et al. Diabetes Care 46(Suppl. 1), S5–S9 (2022).
Grunvald, E. et al. Gastroenterology 163, 1198–1225 (2022).
Uerlich, M. F., Yumuk, V., Finer, N., Basdevant, A. & Visscher, T. L. Obes. Facts 9, 273–283 (2016).
Meikle, A. et al. Semaglutide for managing overweight and obesity: technology appraisal guidance (UK NICE, 2023).
Cohen, J. Forbes (11 June 2023).
Kyle, T. K. & Stanford, F. C. Obesity 24, 1832 (2016).
Jannah, N., Hild, J., Gallagher, C. & Dietz, W. Obesity 26, 1834–1840 (2018).
Sumarsono, A. et al. Diabetes Care 43, 2684–2690 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Waldrop, S.W., Johnson, V.R. & Stanford, F.C. Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity. Nat Med 30, 22–25 (2024). https://doi.org/10.1038/s41591-023-02669-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02669-x